Mundhenke C - Search Results

1

Expression and regulation of tumor suppressor gene maspin in breast cancer.

Maass N, Nagasaki K, Ziebart M, Mundhenke C, Jonat W. Maass N, et al. Among authors: mundhenke c. Clin Breast Cancer. 2002 Oct;3(4):281-7. doi: 10.3816/CBC.2002.n.032. Clin Breast Cancer. 2002. PMID: 12425757

2

Model to determine resistance and leakage-dependent flow on flow performance of laparoscopic insufflators to predict gas flow rate of cannulas.

Jacobs VR, Morrison JE Jr, Mundhenke C, Golombeck K, Jonat W, Harder D. Jacobs VR, et al. Among authors: mundhenke c. J Am Assoc Gynecol Laparosc. 2000 Aug;7(3):331-7. doi: 10.1016/s1074-3804(05)60475-6. J Am Assoc Gynecol Laparosc. 2000. PMID: 10924626

3

Sexual activity as cause for non-surgical pneumoperitoneum.

Jacobs VR, Mundhenke C, Maass N, Hilpert F, Jonat W. Jacobs VR, et al. Among authors: mundhenke c. JSLS. 2000 Oct-Dec;4(4):297-300. JSLS. 2000. PMID: 11051188 Free PMC article.

4

Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas.

Ohike N, Maass N, Mundhenke C, Biallek M, Zhang M, Jonat W, Lüttges J, Morohoshi T, Klöppel G, Nagasaki K. Ohike N, et al. Among authors: mundhenke c. Cancer Lett. 2003 Sep 25;199(2):193-200. doi: 10.1016/s0304-3835(03)00390-2. Cancer Lett. 2003. PMID: 12969792

5

The FACE trial: letrozole or anastrozole as initial adjuvant therapy?

Jonat W, Mundhenke C. Jonat W, et al. Among authors: mundhenke c. Cancer Invest. 2007 Feb;25(1):14-8. doi: 10.1080/07357900701226990. Cancer Invest. 2007. PMID: 17364552 Clinical Trial.

6

Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.

Gieseler F, Lühr I, Kunze T, Mundhenke C, Maass N, Erhart T, Denker M, Beckmann D, Tiemann M, Schulte C, Dohrmann P, Cavaillé F, Godeau F, Gespach C. Gieseler F, et al. Among authors: mundhenke c. Thromb Haemost. 2007 Jun;97(6):1023-30. Thromb Haemost. 2007. PMID: 17549306

7

Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer.

Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Bauer M, et al. Among authors: mundhenke c. Breast Cancer Res Treat. 2008 Apr;108(3):389-97. doi: 10.1007/s10549-007-9619-3. Epub 2007 Jun 7. Breast Cancer Res Treat. 2008. PMID: 17554627

8

[Malignant tumors of the uterus].

Mundhenke C, Bauerschlag D, Fischer D, Friedrich M, Maass N. Mundhenke C, et al. Ther Umsch. 2007 Jul;64(7):381-8. doi: 10.1024/0040-5930.64.7.381. Ther Umsch. 2007. PMID: 17948755 Review. German.

9

Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.

Mundhenke C, Weigel MT, Sturner KH, Roesel F, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Hilpert F, Jonat W, Maass N. Mundhenke C, et al. J Cancer Res Clin Oncol. 2008 Dec;134(12):1397-405. doi: 10.1007/s00432-008-0408-0. Epub 2008 May 9. J Cancer Res Clin Oncol. 2008. PMID: 18465140

10

Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.

Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, Mundhenke C. Weigel MT, et al. Among authors: mundhenke c. Cancer Lett. 2009 Jan 8;273(1):70-9. doi: 10.1016/j.canlet.2008.07.040. Epub 2008 Sep 21. Cancer Lett. 2009. PMID: 18809244

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters